Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial.
Parkinsonism Relat DisordJul 29, 2026 (epub)
Clinical ResearchNeurology
Massimo Marano, Andrea Pilotto, Giancarlo Logroscino et al.
✦ AI-curated · Sources linked
In 30 seconds
The CITIPARK study, a randomized, double-blind, multicenter trial, assessed citicoline's efficacy as an add-on therapy in 474 Parkinson's disease patients on stable dopaminergic treatments. Citicoline significantly improved the likelihood of achieving a minimal clinically important difference on the MDS-UPDRS total score (OR 2.06, 95% CI 1.06-3.99; P=0.031) compared to placebo.
Key findings
- Citicoline increased the likelihood of achieving a minimal clinically important difference on the MDS-UPDRS total score (OR 2.06).
- Motor function improved significantly in the citicoline group (MDS-UPDRS III -2.97 vs -0.13; p=0.009).
- Greater improvement on CGI-II and CGI-III was observed in the citicoline group (3.26 vs 3.59; p=0.021 and 9.30 vs 10.38; p=0.018).
- Adverse events occurred in 22.1% of the citicoline group and 27.1% of the placebo group.
Why it matters
This study highlights the potential of citicoline as a safe and effective adjunct therapy for improving motor and non-motor symptoms in Parkinson's disease, which may enhance patient quality of life.